Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No.
to Rexahn, entitled “5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents.”
This patent covers several new isoquinolinamine compounds and their pharmaceutical composition and method for producing an anti-tumor effect. Studies show that isoquinolinamine compounds have potent anti-tumor properties in several cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma. This class of isoquinolinamine compounds significantly inhibited the growth of paclitaxel (Taxol
) resistant HCT-15 human colorectal cancer cells and tumor growth in an
model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.
Rexahn has been awarded patents for isoquinolinamine compounds in the United States, Mexico, China and now Europe.
“This patent coverage in Europe supports Rexahn’s goal of accelerated development of this exciting new class of anti-cancer compounds,” said Rick Soni, President of Rexahn.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn’s licensees or sublicensees; the success of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.